Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

The Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to aff...

Pfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...

A major private hospital group warns of a crisis for advanced cancer patients under the Central Government Health Scheme. A reimbursement c...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Pfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...

Moderna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.

A superior option is for the government to impose price controls on expensive drugs, whether imported or produced domestically.

Novartis condemned the Supreme Court's dismissal of its patent bid for a blockbuster cancer drug, saying it "discourages future innovation".

Other pharmaceutical companies like Natco Pharma, Cipla and Ranbaxy surged 2-5% after the SC denied patent for Novartis' cancer drug Glivec.

"The DIPP is expected to ask for some more details from different ministries, including the Health Ministry," the source added.

Pfizer Ltd, the India unit of US drugmaker Pfizer Inc, will challenge the country's patent office for revoking a patent for its cancer drug...

Intellectual Property Appellate Board of Chennai dismissed Bayer's plea, seeking a stay on Compulsory License issued to Natco to make Nexav...

Cipla says it has scored a "landmark" court win in a patent challenge launched by Switzerland's Roche Holding over its version of a lung-ca...

The Delhi HC held that Indian pharma major Cipla has not infringed upon the patent right of Swiss drug co F Hoffman La-Roche on a cancer dr...